AmgenvsEmbecta

AMGN and EMBC stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$470.63

Value $254B

+1.06%
AMGN's page

EMBC

Embecta Corp.

$6.43

Value $377M

-0.39%
EMBC's page

Amgen (AMGN) has a market value of $254B and Embecta (EMBC) $377M. Over the last year, with dividends, AMGN moved +43.6% and EMBC -54.4%. The P/E is 27.0 for AMGN and 4.3 for EMBC. Dividend yield: AMGN 2.11%, EMBC 4.97%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$254B

    EMBC$377M

    AMGN is 674 times EMBC

  • Revenue, 12 months

    AMGN$38.9B

    EMBC$1.0B

    AMGN is 38 times EMBC

  • Net income, 12 months

    AMGN$9.4B

    EMBC$88M

    AMGN is 107 times EMBC

  • Operating margin

    AMGN32.4%

    EMBC21.9%

    10.5 points apart

  • ROIC

    AMGN16.2%

    EMBC20.4%

    4.2 points apart

  • P/E

    AMGN27.0

    EMBC4.3

    AMGN is 6.3 times EMBC

  • Dividend yield

    AMGN2.1%

    EMBC5.0%

    2.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+89.9%

EMBC-56.0%

50100150200202420252026
Returns by period
PeriodAMGNWith dividendsEMBCWith dividends
1 year since November 14, 2025+43.6%Price +39.8%-54.4%Price -55.8%
3 years since November 16, 2023+89.9%+23.8% a yearPrice +74.9%-56.0%-23.9% a yearPrice -60.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenEMBCEmbecta

Valuation

AMGNEMBC
Valuation
Price$470.63$6.43
Market value$254B$377M
Enterprise value (EV)$295B$1.6B
P/E27.04.3
P/E, 5-year median23.09.6
P/B17.7–
EV/EBIT23.47.4
Free cash flow yield3.8%43.7%

Results and growth

AMGNEMBC
Results and growth
Revenue, 12 months$38.9B$1.0B
Net income, 12 months$9.4B$88M
Free cash flow, 12 months$9.6B$165M
Earnings per share, 12 months$17.25$1.47
Revenue growth, year on year10.0%-3.8%
Revenue growth a year, past+7.6%over 5 years-0.1%over 5 years
EPS growth a year, past+2.9%over 5 years-26.4%over 5 years

Margins and returns on capital

AMGNEMBC
Margins and returns on capital
Gross margin70.9%59.0%
Operating margin32.4%21.9%
Net margin24.1%8.6%
ROIC16.2%20.4%
ROE87.8%–

Balance sheet

AMGNEMBC
Balance sheet
Cash$13.2B$215M
Total debt$54.0B$1.5B
Net debt / EBITDA2.34.8
Interest cover4.8×–

Dividends and buybacks

AMGNEMBC
Dividends and buybacks
Dividend yield2.1%5.0%
Dividend per share, 12 months$9.94$0.32
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.1%5.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or EMBC

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Embecta?

By market value, Amgen ($254B) is about 673.8 times Embecta ($377M), at today's prices.

How did AMGN and EMBC stock do over the last 3 years?

Since November 16, 2023, AMGN's price moved +74.9% and EMBC's -60.8%. With dividends: AMGN +89.9% (+23.8% a year), EMBC -56.0% (-23.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or EMBC?

The dividend yield at today's price is 2.11% for Amgen and 4.97% for Embecta. Over the last twelve months they paid $9.94 and $0.32 per share.

What is the P/E of AMGN and EMBC?

At today's price, the P/E is 27.0 for AMGN and 4.3 for EMBC. The median of the last five years was 23.0 and 9.6, which shows where each stands against its own past.

Which has the higher profit margins, Amgen or Embecta?

Over the last twelve months, the net margin was 24.1% for Amgen and 8.6% for Embecta, and the operating margin 32.4% and 21.9%. Revenue was $38.9B and $1.0B.

Which is the better investment, Amgen or Embecta?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.